Nicolò Bizzarri1, Vito Chiantera2, Alfredo Ercoli3, Anna Fagotti1, Lucia Tortorella4, Carmine Conte4, Serena Cappuccio1, Mariano Catello Di Donna2, Valerio Gallotta1, Giovanni Scambia1, Giuseppe Vizzielli5. 1. Department of Woman s and Child Health, Fondazione Policlinico Universitario "Agostino Gemelli", IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy (Drs. Bizzarri, Fagotti, Cappuccio, Gallotta, Scambia, and Vizzielli). 2. Division of Gynecologic Oncology, University of Palermo, Palermo, Italy (Drs. Chiantera, and Catello Di Donna). 3. Department of Obstetrics and Gynecology, University of Eastern Piedmont, Novara, Italy (Dr. Ercoli). 4. Department of Woman and Child Health, Fondazione Policlinico Universitario "Agostino Gemelli", IRCCS, Rome, Italy (Drs. Tortorella and Conte). 5. Department of Woman s and Child Health, Fondazione Policlinico Universitario "Agostino Gemelli", IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy (Drs. Bizzarri, Fagotti, Cappuccio, Gallotta, Scambia, and Vizzielli). Electronic address: giuseppevizzielli@yahoo.it.
Abstract
STUDY OBJECTIVE: To assess the feasibility and efficacy of minimally invasive pelvic exenteration (MIPE) in a multi-institutional Italian case series of women with gynecologic cancer and a review of the literature. DESIGN: Retrospective cohort study (Canadian Task Force classification II-2). SETTING: Three Italian university/teaching hospitals: "Agostino Gemelli" Foundation University Hospital in Rome, "ARNAS Civico Di Cristina Benfratelli" Hospital in Palermo, and "Maggiore della Carità" Hospital in Novara. PATIENTS: We reviewed all consecutive cases with gynecologic malignancies in this multi-institutional setting recorded between March 2014 and June 2017. Women with primary or central recurrent/persistent gynecologic cancer considered suitable for exenterative surgery after multidisciplinary tumor board discussion were included. Clinicopathological, perioperative, and survival data were retrieved from the institutional electronic database (STAR center). INTERVENTIONS: All patients underwent total or anterior MIPE with a laparoscopic or robotic approach. MEASUREMENTS AND MAIN RESULTS: Twenty-three patients underwent MIPE during the study period, including 12 (52.1%) by a laparoscopic approach and 11 (47.9%) by a robotic approach. All but 1 woman underwent MIPE for recurrent disease. The overall median operative time was 540 minutes (range, 310-720 minutes) with laparoscopy, slightly longer than with the robotic approach (p = .04). Median estimated blood loss was 400 mL (range, 200-600 mL). R0 resection was achieved in 17 of 23 patients (73.9%). There were no perioperative deaths. Early major postoperative complications occurred in 2 patients (8.7%). The median duration of hospitalization was 10 days (range, 6-33 days). With a median follow-up of 15 months, 11 patients (47.8%) developed recurrence. The median disease-free survival was 11 months (range, 5-18 months). To date, 155 MIPEs for gynecologic cancers have been reported in the literature. Among these, 12.6% had major postoperative complications, and overall postoperative mortality was 0.6%. CONCLUSION: MIPE is a feasible procedure with low rate of intraoperative and postoperative complications. Careful patient selection is crucial to balance perioperative risks and potential survival benefits and to achieve complete tumor resection.
STUDY OBJECTIVE: To assess the feasibility and efficacy of minimally invasive pelvic exenteration (MIPE) in a multi-institutional Italian case series of women with gynecologic cancer and a review of the literature. DESIGN: Retrospective cohort study (Canadian Task Force classification II-2). SETTING: Three Italian university/teaching hospitals: "Agostino Gemelli" Foundation University Hospital in Rome, "ARNAS Civico Di Cristina Benfratelli" Hospital in Palermo, and "Maggiore della Carità" Hospital in Novara. PATIENTS: We reviewed all consecutive cases with gynecologic malignancies in this multi-institutional setting recorded between March 2014 and June 2017. Women with primary or central recurrent/persistent gynecologic cancer considered suitable for exenterative surgery after multidisciplinary tumor board discussion were included. Clinicopathological, perioperative, and survival data were retrieved from the institutional electronic database (STAR center). INTERVENTIONS: All patients underwent total or anterior MIPE with a laparoscopic or robotic approach. MEASUREMENTS AND MAIN RESULTS: Twenty-three patients underwent MIPE during the study period, including 12 (52.1%) by a laparoscopic approach and 11 (47.9%) by a robotic approach. All but 1 woman underwent MIPE for recurrent disease. The overall median operative time was 540 minutes (range, 310-720 minutes) with laparoscopy, slightly longer than with the robotic approach (p = .04). Median estimated blood loss was 400 mL (range, 200-600 mL). R0 resection was achieved in 17 of 23 patients (73.9%). There were no perioperative deaths. Early major postoperative complications occurred in 2 patients (8.7%). The median duration of hospitalization was 10 days (range, 6-33 days). With a median follow-up of 15 months, 11 patients (47.8%) developed recurrence. The median disease-free survival was 11 months (range, 5-18 months). To date, 155 MIPEs for gynecologic cancers have been reported in the literature. Among these, 12.6% had major postoperative complications, and overall postoperative mortality was 0.6%. CONCLUSION: MIPE is a feasible procedure with low rate of intraoperative and postoperative complications. Careful patient selection is crucial to balance perioperative risks and potential survival benefits and to achieve complete tumor resection.
Authors: Stefano Cianci; Martina Arcieri; Giuseppe Vizzielli; Canio Martinelli; Roberta Granese; Marco La Verde; Anna Fagotti; Francesco Fanfani; Giovanni Scambia; Alfredo Ercoli Journal: Front Surg Date: 2021-11-30